Ipamorelin vs Setmelanotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →Side-by-Side Comparison
| Aspect | Ipamorelin | Setmelanotide |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 1 mg–3 mg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 8–12 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. |
| Typical Dosage | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. |
| Administration | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. |
| Side Effects | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. |
| Best For |
What They Have in Common
Ipamorelin, Setmelanotide are both commonly used for:
Key Differences
Unique to Ipamorelin:
Which Has Stronger Evidence?
| Goal | Ipamorelin | Setmelanotide |
|---|---|---|
| Fat Loss | high | high |
Key Studies
Ipamorelin
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
Animal reproduction science, 2024
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Physiology & behavior, 2024
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
International journal of colorectal disease, 2014
Setmelanotide
- Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Obesity (Silver Spring, Md.), 2026
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine, 2026
- Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome.
The Journal of clinical endocrinology and metabolism, 2026
Ready to Learn More?
Looking for trusted sources?